FIELD: biotechnology.
SUBSTANCE: invention relates to new therapeutic proteins and can be used in medicine. The invention discloses a bispecific fusion protein in which the second binding structural domain is inserted into the hinge region of a full length immunoglobulin G (IgG). Such a fusion protein has the same expression and production advantages as the original IgG, does not affect the binding activity of the Fab region of the fusion protein, and further improves stability and provides a longer half-life.
EFFECT: invention can be used in the treatment of various malignant neoplasms.
41 cl, 6 ex, 11 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| MUTANT NITRILE HYDRATASE, NUCLEIC ACID WHICH ENCODES SAID MUTANT NITRILE HYDRATASE, EXPRESSION VECTOR AND TRANSFORMANT CONTAINING SAID NUCLEIC ACID, METHOD OF PRODUCING SAID MUTANT NITRILE HYDRATASE AND METHOD OF PRODUCING AMIDE COMPOUND | 2017 |
|
RU2736086C1 |
| TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING CROSSOVER FORMAT WITH DOUBLE VARIABLE DOMAIN (CODV) FOR TREATING INFECTION CAUSED BY HIV | 2020 |
|
RU2820164C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
